CTX-8371 for Advanced Cancer

Phase 1

Recruiting

Research Sponsored by Compass Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose of ctx-8371 (cycle 1 day 1, cycle = 2 weeks) until 30 days after the last dose of ctx-8371, average of 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug called CTX-8371 in patients with advanced cancer. The study will be done in two parts: one to find the best dose of the drug and another to

Who is the study for?

This trial is for adults with advanced cancers like breast cancer, lung cancer, or melanoma that have stopped responding to standard treatments. Participants must have tried a PD-1/PD-L1 inhibitor and, if they have a specific mutation (BRAF V600), also BRAF/MEK inhibitors.

What is being tested?

The study tests CTX-8371 as a solo treatment in two parts: first finding the right dose and then seeing how well it works at that dose. It's for patients whose cancers haven't responded to other therapies.

What are the potential side effects?

As this is an early-phase trial of CTX-8371, side effects are being studied; however, common side effects may include fatigue, nausea, skin reactions, or allergic responses typical of new cancer drugs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first dose of ctx-8371 (cycle 1 day 1, cycle = 2 weeks) until 30 days after the last dose of ctx-8371 (up to 2 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first dose of ctx-8371 (cycle 1 day 1, cycle = 2 weeks) until 30 days after the last dose of ctx-8371 (up to 2 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose of ctx-8371 (cycle 1 day 1, cycle = 2 weeks) until 30 days after the last dose of ctx-8371 (up to 2 years) for reporting.